AU663479B2 - Use of NADH and NADPH as energy substitutes - Google Patents
Use of NADH and NADPH as energy substitutes Download PDFInfo
- Publication number
- AU663479B2 AU663479B2 AU10392/92A AU1039292A AU663479B2 AU 663479 B2 AU663479 B2 AU 663479B2 AU 10392/92 A AU10392/92 A AU 10392/92A AU 1039292 A AU1039292 A AU 1039292A AU 663479 B2 AU663479 B2 AU 663479B2
- Authority
- AU
- Australia
- Prior art keywords
- nadh
- nadph
- nicotinamide
- adenine
- reduced form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/153—Nucleic acids; Hydrolysis products or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Detergent Compositions (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Dental Preparations (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Use is described of nicotinamide adenine dinucleotide in its reduced form (NADH) and/or nicotinamide adenine dinucleotide phosphate in its reduced form (NADPH) and/or a physiologically tolerated salt of the same for energy substitution in humans or animals, as is a foodstuff or confectionary product for human consumption or a feedstuff for animal consumption having a content of the substances mentioned.
Description
P/00/011 28/5191 Regulation 3.2(2)
AUSTRALIA
Patents Act 1990 t3 47
ORIGINAL
COMPLETE SPECIFICATION STANDARD PATENT It C C IC C It 4111 4 Ct ft C II It C I t C C (444 t I C 4 C 4
C
11.49.
C 4 Application Number: Lodged: Invention Title: USE OF NADH AND NADPH AS ENERGY SUBSTITUTES It II I S 4
I
.4 4 S S 0C The following statement is a full description of this invention, including the best method of performing it kinown to k Use of NADH and NADPH as energy substitutes.
The present application relates to a novel use of nicotinamide-adeninedinucleotide in its reduced form (NADH) and/or nicotinamide-adeninedinucleotide phosphate in its reduced form (NADPH) and/or a physiologically compatible salt thereof, as well as a food or beverage for human consumption or a feed for animal consumption with a content of said substances, For some years now, particularly in the sporting sector, the most varied energy-increasing products have been in favour, either in the form of the largely forbidden anabolics for increasing muscle formation, or the relatively harmless, but largely ineffective products such as sports o- drinks, chocolate bars, etc.
o e The problem of the present invention is to make available products, which act as highly effective and completely harmless energy substitutes in the human or animal body.
According to the invention this problem is solved by the use of nicotinamide-adenine-dinucleotide in its reduced form (NADH) and/or nicotinamide-adenine-dijicleotide phosphate in its reduced form (NADPH) and/or a physiologically acceptable salt thereof for energy substitution in S the human or animal body. According to a preferred embodiment of the invention said substances are added to a food or drink or to a feed.
S* Alternatively the substances can also be used as the single active ingredient or active ingredient component in a medicamern i improving efficiency and/or for retarding deterioration and/or aging processes. A particularly preferred use of said substances is as or in a geriatric product.
With particular preference NADH and/or NADPH and/or the physiologically accepte.le salt thereof is administered in a quantity which supplies -2the human or animal body with a single dose of 0.01 to 1.0 mg/kg of body weight.
The invention also relates to a food or beverage for human consumption having a content of nicotinamide-adenine-dinucleotide in its reduced form (NADH) and/or nicotinamide-adenine-dinucleot phosphate in its reduced form (NADPH) and/or a physiologically compatible salt thereof, said substances preferably being contained in a quantity enabling the human body to be supplied with 0.01 to 1.0 mg/kg of body weight of said substances per daily consumption unit.
Finally, the invention relates to a feed for animal consumption having j I a content of nicotinamide-adenine-dinucleotide in its reduced form (NADH) nd/or nicotinamide-adenine-dinucleotide phosphate in its reduced form (NADPH) and/or a physiologically compatible salt thereof, said substances preferably being contained in a quantity such that the animal body is supplied with 0.01 to 1.0 mg/kg of body weight per daily consumption unit.
The "daily consumption unit" is understood to be that quantity of a food or beverage or feed, which is normally consumed every day by a S specific human or animal. As NADH and NADPH are endogenic substances an increase in this quantity in individual cases is not critical, because any overdoses will not have harmful effects on the organism.
The invention is based on the finding that NADH and NADPH, apart from other energy-rich molecules such as adenine triphosphate (ATP), store in the body the energy released by energy-supplying nutrients such as carbohydrates, fats and proteins and make same available to biosynthetic processes.
The most important function of NADH is its driving force for cell respiration. When using oxygen NADH forms water and three ATP molecules in accordance with the following formula: i f 3- NADH H +1/2 0 2 3 Pi 3 ADP- NAD 3 ATP 4H 2 0 Thus, with one NADH molecule three ATP molecules are obtained, which have an energy of in all approximately 21 kilocalories. This process is called oxidative phosphorylation. The quantitative significance of this process for the human body can be demonstrated by a simple mathematical example. A person weighing 70kg requires roughly 2800 kilocalories daily when at rest. This energy quantity can be obtained by the hydrolysis of approximately 384 mole of ATP corresponding to 190 kg of said substance. However, the ATP quantity present in the human body is only 50g. Therefore the organism must produce the remaining 189.95kg every day.
o 0 The supply of NADH or NADPH makes this work much easier for the organism, because it consequently has greater energy reserves. It is also possible to stimulate the many other metabolic reactions catalyzed by the S two coenzymes NADH and NADPH. As ATP plays an important part in regulating the vascular tonus, muscle contraction, in cardiovascular functions, in neurotransmission and in thrombocyte aggregation, which are all central parameters for the well-being and efficiency of humans and animals, an increase in the number of ATP molecules by supplying NADH or NADPH not only leads to an energy substitution, but to an improvement in the general state of health and to a retarding of deterioration and aging processes.
The use of the inventive compounds is completely harmless for the human and animal organism, because they are endogenic substances. Thus, in clinical tests on humans up to 20 times higher concentrations were admini istered than the indicated individual dose maximum in humans in the form of intravenous injections. No side-effects were observed. Research has shown that if the organism is supplied with too much NADH or NADPH, it is immediately oxidized to NAD or NADP and this is a reversible equilibrium reaction.
1 s 4 At present there is no clear picture concerning further possible action mechanisms of NADH or NADPH leading to the further positive effects on the organism described in the following description of cases.
Case Descriptions Case 1: Tennis professional, aged 24, male, was given 5mg of NADH twice weekly in tablet form. After three weeks subjective and objective increase in the body efficiency and physical fitness, reduced fatigue after matches, reduced sleep requirement, increased alertness and attentiveness.
0 00 °o S I Case 2: Manager, aged 49, male, with a fourteen hour working day, was given a chocolate bar containing lOmg of NADPH once weekly. After taking thee times there was a clear increased efficiency, reduced fatigue, able to stop drinking coffee, reduced sleep requirement, increased physical and intellectual activity at the end of the working day.
Case 3: Artist, aged 70, male, uninterested in work, inactive, sleeps until noon, was given twice weekly (for consumption in one day) one litre of a refreshing drink containing 15mg of NADH. After three weeks, *4 active, energy-laden, gets up early, works all day, has a good mood and feels physically and intellectually better. After stopping NADH f f administration for four weeks, a return to the previous state with the.
old complaints. Treatment resumed with tablets containing 5mg of NADPH twice weekly. After one week clear improvement and after fourteen days I restoration of the original active well-being.
Case 4: Six year old racehorse, which had not been successful for a long time and lacking interest in food or movement. Following a six week administration period of feed pellets with a content of 0.5 mg/kg of body weight per daily consumption unit, clear increase in food and movement, much fresher and more active, with a first racing success after ten weeks treatment.
Ii 4 The features disclosed in the description and claims can be essential to the realization of the different embodiments of the invention, either singly or in the form of random combinations.
I 4 4 14 4494 a ft I 4, L4 ~3 4 4 4 It; I 9 4.4; 4 4 4 It 4 a A:
(C
44 44 44 1 a
I
Claims (5)
1. Use of one or more compounds from the group consisting of nicotinamide-adenine-dinucleotide in its reduced form (NADH), nicotinamide- adenine-dinucleotide phosphate in its reduced form (NADPH), and a physiologically compatible salt of NADH or NADPH for energy substitution in the human and animal body.
2. Use according to claim 1 as an additive to a food or drink.
3. Use according to claim 1 as an additive to a feed. Use according to one of the claims 2 to 4, characterized in that the one or more compounds is administered in a quantity giving the animal or human body a total single dose of 0.01 to 1.0 mg/kg of body weight.
6. Food or beverage used for energy substitution and for human consumption with a content of one or more compounds from the group consisting of nicotinamide-adenine-dinucleotide in its reduced form (NADH), nicotinamide-adenine-dinucleotide phosphate in its reduced form (NADPH) and a physiologically compatible salt of NADH or NADPH as a food additive in adjunct with edible, non-toxic carriers and excipients. I 7
7. Feed for animal consumption used for energy substitution and with a content of one or more compounds from the group consisting of nicotinamide- adenine-dinucleotide in its reduced form (NADH), nicotinamide-adenine- dinucleotide phosphate in its reduced form (NADPH) and a physiologically compatible salt of NADH or NADPH as a food additive in adjunct with edible, non-toxic carriers and excipients. DATED this 2nd day of August, 1995 JORG BIRKMAYER I rt r S" WATERMARK PATENT TRADEMARK ATTORNEYS 290 BURWOOD ROAD S" HAWTHORN VICTORIA 3122 AUSTRALIA tL I t I V -8- ABSTRACT Use of nicotinamide-adenine-dinucleotide in its reduced form (NADH) and/or nicotinamide-adenine-dinucleotide phosphate in its reduced form (NADPH) and/or a physiologically compatible salt thereof for energy substitution in the human or animal body, as well as a food or drink for human consumption or a feed for animal consumption having a content of said substances. a 1 3 I i C it ti II I j0 I I_-
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4102240 | 1991-01-24 | ||
DE4102240A DE4102240C1 (en) | 1991-01-24 | 1991-01-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
AU1039292A AU1039292A (en) | 1992-07-30 |
AU663479B2 true AU663479B2 (en) | 1995-10-12 |
Family
ID=6423720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU10392/92A Ceased AU663479B2 (en) | 1991-01-24 | 1992-01-23 | Use of NADH and NADPH as energy substitutes |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0496479B1 (en) |
JP (1) | JP2533709B2 (en) |
AT (1) | ATE112664T1 (en) |
AU (1) | AU663479B2 (en) |
BR (1) | BR9200207A (en) |
CA (1) | CA2059510C (en) |
DE (2) | DE4102240C1 (en) |
DK (1) | DK0496479T3 (en) |
ES (1) | ES2061313T3 (en) |
FI (1) | FI920323A (en) |
HU (1) | HU9200213D0 (en) |
IE (1) | IE69861B1 (en) |
NO (1) | NO304672B1 (en) |
ZA (1) | ZA92275B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2167104A1 (en) * | 1995-01-17 | 1996-07-18 | Joerg G.D. Birkmayer | Nadh and nadph therapeutic agents for nasal, sublingual, rectal and dermal administration |
US5712259A (en) * | 1996-04-22 | 1998-01-27 | Birkmayer Pharmaceuticals | NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome |
US5668114A (en) * | 1996-05-08 | 1997-09-16 | Birkmayer Pharmaceuticals | NADH and NADPH pharmaceuticals for treating hypertension |
IT1318565B1 (en) * | 2000-06-09 | 2003-08-27 | World Pharma Tech Ltd | NADH OCTOCOSANOL EVITAMIN E PROENERGETIC FOOD SUPPLEMENT |
US20040126751A1 (en) * | 2002-12-27 | 2004-07-01 | Birkmayer Jorg G.D. | Method of prolonging the life-span of living cells using NADH, NADPH and ADP-ribose |
DE102008010245B4 (en) * | 2008-02-20 | 2011-02-10 | Emag Holding Gmbh | Method for grinding wavy workpieces |
DE102014103443A1 (en) * | 2014-03-13 | 2015-09-17 | Jürgen Ruhlmann | Composition for use in the treatment of fatigue, lack of concentration, withdrawal symptoms, headaches and colds, in particular loss of power, hangover and fatigue |
WO2020021734A1 (en) * | 2018-07-26 | 2020-01-30 | オリジンバイオテクノロジー株式会社 | Functional chicken eggs and method for producing same |
DE202022000567U1 (en) | 2022-03-06 | 2022-03-16 | Penta Phi Eg | Liposomal formulation |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3594475A (en) * | 1968-04-24 | 1971-07-20 | Kyowa Hakko Kogyo Kk | Method of treating and preventing the side effects of antibiotics |
EP0107161B1 (en) * | 1982-10-26 | 1989-08-09 | CTA Finanz AG | Device and process for optimising the tissue mass of organs within the genetic fluctuation range in humans and animals |
IT1162938B (en) * | 1983-08-26 | 1987-04-01 | Dino Spisni | COMPOSITION FOR THE TREATMENT OF MALIGNANT CANCERS, IN PARTICULAR ON ANIMALS |
JPS60126220A (en) * | 1983-12-09 | 1985-07-05 | Otsuka Pharmaceut Factory Inc | Nucleic acid component composition |
ES2007350A6 (en) * | 1987-05-29 | 1989-06-16 | Ganadera Union Ind Agro | Food products enriched with nucleosides and/or nucleotides and preparation thereof. |
DE58905201D1 (en) * | 1988-03-01 | 1993-09-16 | Birkmayer Walther | AGENT FOR TREATING THE PARKINSON SYNDROME. |
AT397201B (en) * | 1988-06-03 | 1994-02-25 | Birkmayer Joerg Ddr | USE OF THE ENZYME COFACTOR NADPH IN THE PRODUCTION OF A MEDICINAL PRODUCT |
-
1991
- 1991-01-24 DE DE4102240A patent/DE4102240C1/de not_active Expired - Lifetime
- 1991-12-27 JP JP3345766A patent/JP2533709B2/en not_active Expired - Fee Related
-
1992
- 1992-01-06 DK DK92250002.0T patent/DK0496479T3/en active
- 1992-01-06 DE DE59200603T patent/DE59200603D1/en not_active Expired - Fee Related
- 1992-01-06 EP EP92250002A patent/EP0496479B1/en not_active Expired - Lifetime
- 1992-01-06 AT AT92250002T patent/ATE112664T1/en not_active IP Right Cessation
- 1992-01-06 ES ES92250002T patent/ES2061313T3/en not_active Expired - Lifetime
- 1992-01-14 ZA ZA92275A patent/ZA92275B/en unknown
- 1992-01-16 CA CA002059510A patent/CA2059510C/en not_active Expired - Fee Related
- 1992-01-23 AU AU10392/92A patent/AU663479B2/en not_active Ceased
- 1992-01-23 BR BR929200207A patent/BR9200207A/en not_active Application Discontinuation
- 1992-01-23 IE IE920198A patent/IE69861B1/en not_active IP Right Cessation
- 1992-01-23 HU HU9200213A patent/HU9200213D0/en unknown
- 1992-01-23 NO NO920315A patent/NO304672B1/en not_active IP Right Cessation
- 1992-01-24 FI FI920323A patent/FI920323A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2533709B2 (en) | 1996-09-11 |
ATE112664T1 (en) | 1994-10-15 |
NO304672B1 (en) | 1999-02-01 |
ZA92275B (en) | 1992-12-30 |
IE69861B1 (en) | 1996-10-16 |
NO920315D0 (en) | 1992-01-23 |
IE920198A1 (en) | 1992-07-29 |
JPH05262652A (en) | 1993-10-12 |
ES2061313T3 (en) | 1994-12-01 |
EP0496479A1 (en) | 1992-07-29 |
DE4102240C1 (en) | 1992-04-09 |
HU9200213D0 (en) | 1992-04-28 |
AU1039292A (en) | 1992-07-30 |
CA2059510C (en) | 1997-06-10 |
DK0496479T3 (en) | 1995-04-18 |
CA2059510A1 (en) | 1992-07-25 |
FI920323A (en) | 1992-07-25 |
EP0496479B1 (en) | 1994-10-12 |
FI920323A0 (en) | 1992-01-24 |
DE59200603D1 (en) | 1994-11-17 |
NO920315L (en) | 1992-07-27 |
BR9200207A (en) | 1992-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Murphy et al. | Regular induction of hypomania by L-dopa in “bipolar” manic-depressive patients | |
Young | Growth and diabetes in normal animals treated with pituitary (anterior lobe) diabetogenic extract | |
Westerfeld et al. | Metabolism and caloric value of alcohol | |
USRE43029E1 (en) | Process for preparing a creatine heterocyclic acid salt and method of use | |
JP5714227B2 (en) | Anti-fatigue agent and oral composition containing andrographolide as active ingredient | |
EP1252892A1 (en) | Composition for reducing mental fatigue, composition for maintaining and enhancing concentration, and composition for maintaining and enhancing mental vigor | |
CN1272790A (en) | Method for promoting weight and fat loss with composition comprising hydroxycitrate, carnitine and pyruvate promotor | |
CN102448452A (en) | Dietary supplement comprising alpha keto acids for supporting diabetes therapy | |
JP6629595B2 (en) | Synergistic dietary supplement composition for enhancing physical performance and energy levels | |
US20050249713A1 (en) | Dietary supplement energy-providing to skeletal muscles and protecting the cardiovascular tract | |
AU663479B2 (en) | Use of NADH and NADPH as energy substitutes | |
CN102273581A (en) | Compound sweetener with high sweetness | |
US20010020007A1 (en) | Vitamin preparations for reducing oxygen consumption during physical efforts | |
Littman et al. | Acceleration of growth of sarcoma 180 with pyridoxamine and retardation with penicillamine. | |
Gibala | Dietary protein, amino acid supplements, and recovery from exercise | |
JPH0995448A (en) | Increase in biotin concentration in blood and biotin-containing beverage or food product | |
US6703371B1 (en) | Preparations for reducing oxygen consumption during physical efforts | |
Elvehjem | The Biological Significance of Nicotinic Acid: Harvey Lecture, November 16, 1939 | |
EP2042170B1 (en) | Creatine composition and use | |
US20230025468A1 (en) | Method and a dietary composition on regulation, treatment, and prevention of obesity | |
Burke | Branched-chain amino acids (BCAAs) and athletic performance | |
EP0920321A1 (en) | Vitamine preparations for reducing oxygen consumption during physical efforts | |
UA127073C2 (en) | HERODIETICAL MIXTURE FOR ENTERAL NUTRITION FOR PERSONS WITH DIABETES DISEASE | |
JPWO2014163151A1 (en) | Yeast culture and oral composition | |
CZ5849U1 (en) | Special natural stimulant of organism |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |